UK: Brexit Update – Continue To Prepare For A Hard Brexit

Last Updated: 31 May 2018
Article by Nina O'Sullivan and Natasha Pearman

In the last edition of Inside Life Sciences, we reported on the draft EU withdrawal agreement that had been provisionally agreed between the UK and the EU27, including in relation to a proposed transition period following the UK's intended exit from the EU, until 31 December 2020. As is well known, 'nothing is agreed until everything is agreed' but it is hoped that final agreement on the withdrawal arrangements will be in place by October 2018 (subject to there being sufficient progress on the complex issue relating to the Irish border).

However, whilst the proposed transitional period removes the fear of a 'cliff edge' in March 2019, it remains too short, and too uncertain for the life sciences industry, with its need for long lead times. Accordingly, the industry is taking the heed of the European Medicines Agency which continues to reiterate that 'industry should not rely on the 'transition period'. Even if there is commitment to reaching an agreement on the UK's orderly withdrawal, this should not dispense from ensuring preparedness'.

The MHRA's approach meanwhile is that that it is possible for agreement to be reached which will allow an ongoing active regulatory relationship, as highlighted in its recently published five year corporate plan, as well as allowing the UK to explore 'interest in new global partnerships'.

The divergence between the approach of the EMA and MHRA was highlighted at the recent EU Pharmaceutical Law Forum where Managing Associate Natasha Pearman appeared on a panel, which included Jonathan Mogford of the MHRA. Sandra Vanlievendael from the EMA was also in attendance and responded directly to a number of questions from participants.  In particular, Mr Mogford expressed the hope that more pragmatic discussions will take place in phase 2 of the negotiations, and the belief that a specific deal for pharma can be achieved. It is clear that the welfare of patients across the EU (i.e., not just the UK) needs to take centre stage in the ongoing political discussions, and be at the forefront of the negotiators' minds, with associate membership being the preferred outcome.

Meanwhile, in a speech at Jodrell Bank on 21 May on the Industrial Strategy, the Prime Minster confirmed that the UK would wish to 'fully associate with the excellence-based European science and innovation programmes – including the successor to Horizon 2020' post Brexit, recognising that that this would involve an 'appropriate' financial contribution, but in the expectation of a 'suitable' level of influence.

Transition period and re-allocation of UK's centralised portfolio

In addition to the uncertainty and inadequate length of the proposed transition period, there is another aspect that is causing concern. Following publication of the draft withdrawal agreement, Dr Sarah Wollaston MP, Chair of the House of Commons Health and Social Care Committee, wrote to the Secretary of State seeking clarification of the UK/EMA relationship during the transition period. In particular, as the UK will be subject to EU rules and laws during the transition, but will no longer be able to participate in the EMA decision making process, she asked whether this would limit the UK to being a 'rule taker', rather than a rule maker during the transition period. Furthermore, the relationship during the proposed transition period would be more restrictive than the ambition of a future wider role of associate membership.  

This certainly appears to be the case, with the EMA confirming that, despite the transition period, the UK will no longer take part in decision making or have a role as a leading authority (i.e., as a rapporteur or reference Member State) after March 2019.  The EMA has begun the process of redistributing over 370 centrally authorised products, which were in the MHRA portfolio, to new rapporteurs and co-rapporteurs from 30 March 2019. This covers the post-authorisation stage of a medicine's lifecycle. Generic medicines will be allocated to national competent authorities that have traditionally participated less in EMA evaluations but which want to increase their involvement.

Report published by BEIS Committee

Following the report by the Health and Social Care Committee in March, the Business, Energy and Industrial Strategy Committee has now published its report on the implications of Brexit for the industry. The report reiterates the industry's concern that a no deal would be disastrous for the sector, and risks a damaging effect on UK and EU patients. It notes that, despite seeking out 'any potential benefits to the UK pharmaceutical sector from Brexit', any 'small gains would be hugely outweighed by additional costs or the loss of access to existing, successful markets', there being 'no evidence of new trade routes from which the UK could benefit'.

The report reiterates many of the concerns that have been expressed for some time by the industry in relation to the transition period, supply chain issues, regulatory divergence, tariffs, non-tariff barriers, skills shortages, access to funding and the impact on clinical trials.

As for the EMA, the report highlights that the EU27 expect the UK to be responsible for the existing lease on its Canary Wharf premises (which runs until 2039).  It suggests that the EMA should retain a residual staff in the UK to support a continued relationship between the EMA and MHRA, but also to support those EMA staff who do not wish to leave the UK (it is understood that a minimum 20% of EMA employees do not wish to move to Amsterdam).

What will happen next?

Aside from the general ongoing discussions between the EU and UK negotiators, a number of updates impacting on the pharma industry will be published in forthcoming months including:

  • EMA survey on Brexit preparedness: the EMA issued a survey in January 2018 of preparedness levels of MA holders of centrally authorised medicines located in the UK, and those who have quality control, batch release and/or import manufacturing sites or a qualified person for pharmacovigilance in the UK, on their plans to submit transfers, notifications or variations to their marketing authorisations. This survey should report its results soon.
  • Having published its interim report, the Migration Advisory Committee will be reporting in September 2018 on the impact of Brexit on the UK labour market, i.e., in relation to EEA nationals working in the UK. The Government rejected a request by the Science and Technology Committee that the report be expedited in relation to science and innovation.
  • The Government has commissioned a report by Ernst & Young on the impact of Brexit on supply chains in the pharmaceutical sector. However, it is not clear yet whether this report will be published.  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Mishcon de Reya
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Mishcon de Reya
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions